US FDA's de novo proposal will not result in significant time saving, says medtech association
This article was originally published in SRA
Executive Summary
US medtech industry association AdvaMed does not think that the Food and Drug Administration's proposal to streamline its de novo process (that is used for innovative, low- to moderate-risk devices that cannot be cleared by the pre-market notification, or 510(k), process) will result in any significant time saving for medtech companies as is being claimed by the agency1,2.
You may also be interested in...
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.
EMA Presses On With Keenly-Awaited Guidance On How To Use Patient Experience Data
While the International Council of Harmonisation is developing a harmonized approach to patient-focused drug development, the European Medicines Agency has heeded calls for “prompt guidance” to support the systematic inclusion of patient experience data in regulatory submissions.